Cisplatin, Carboplatin, Oxaliplatin 투여로 인한 말초신경병증에 대한 평가
Evaluation of Chemotherapy Induced Peripheral Neuropathy by Cisplatin, Carboplatin and Oxaliplatin
0
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background: Chemotherapy-induced peripheral neuropathy (CIPN) involving sensory and motor nerve damage or dysfunction is a common and serious clinical problem that affects many patients receiving cancer treatment. This condition may pose challenges for the clinician to diagnose and manage, particularly in patients with coexisting conditions or disorders that involve the peripheral nervous system. Many chemotherapeutic agents used today are associated with the development of serious and dose-limiting CIPN that can adversely affect the administration of planned therapy and can impair quality of life by interference with the patients’ activities of daily living. The most important clinical objective in the evaluation of patients with CIPN is to determine their level of functional impairment involving activities of daily living. These findings are used to make medical decisions to continue, modify, delay, or stop treatment. The most commonly reported drugs to cause CIPN include taxanes, platinum agents, vinca alkaloids, thalidomide, and bortezomib. We aimed to determine PN incidence during cisplatin, carboplatin and oxaliplatin administration. Methods: We collected data from 125 patients who received at least one cycle of cisplatin, carboplatin or oxaliplatin. They completed a self-reported questionnaire and items related to their disease and peripheral neuropathy. The investigators filled in part of items about disease and treatment. Patient Neurotoxicity Qeustionnaire developed by Bionumerik company were applied for PN assessment. Results: The incidences of sensory neurotoxicities of cisplatin, carboplatin and oxaliplatin were respectively 23%, 56% and 50%. The incidences of motor neurotoxicities of cisplatin, carboplatin and oxaliplatin were respectively 18%, 42% and 19%. The incidences of severe neurotoxicities of cisplatin, carboplatin and oxaliplatin were respectively 13%, 28% and 14%. The incidences of PN were associated with cumulative dose but not age, gender and concurrent illness. 19.2% of the patients (24/125) were prescribed with gabapentin, nortriptyline or gabapentin plus nortriptyline to reduce these peripheral symptoms and 75% of the patients answered the drug were effective. Conclusion: Incidence of PN after cisplatin or oxaliplatin administration is cumulative dose-related. Physician-based assessments under-reported the incidence and severity of CIPN. To overcome this limitation, diagnostic tools specifically designed to assess peripheral neuropathy severity associated with chemotherapy must be developed.
Abstract
Background: Chemotherapy-induced peripheral neuropathy (CIPN) involving sensory and motor nerve damage or dysfunction is a common and serious clinical problem that affects many patients receiving cancer treatment. This condition may pose challenges for the clinician to diagnose and manage, particularly in patients with coexisting conditions or disorders that involve the peripheral nervous system. Many chemotherapeutic agents used today are associated with the development of serious and dose-limiting CIPN that can adversely affect the administration of planned therapy and can impair quality of life by interference with the patients’ activities of daily living. The most important clinical objective in the evaluation of patients with CIPN is to determine their level of functional impairment involving activities of daily living. These findings are used to make medical decisions to continue, modify, delay, or stop treatment. The most commonly reported drugs to cause CIPN include taxanes, platinum agents, vinca alkaloids, thalidomide, and bortezomib. We aimed to determine PN incidence during cisplatin, carboplatin and oxaliplatin administration. Methods: We collected data from 125 patients who received at least one cycle of cisplatin, carboplatin or oxaliplatin. They completed a self-reported questionnaire and items related to their disease and peripheral neuropathy. The investigators filled in part of items about disease and treatment. Patient Neurotoxicity Qeustionnaire developed by Bionumerik company were applied for PN assessment. Results: The incidences of sensory neurotoxicities of cisplatin, carboplatin and oxaliplatin were respectively 23%, 56% and 50%. The incidences of motor neurotoxicities of cisplatin, carboplatin and oxaliplatin were respectively 18%, 42% and 19%. The incidences of severe neurotoxicities of cisplatin, carboplatin and oxaliplatin were respectively 13%, 28% and 14%. The incidences of PN were associated with cumulative dose but not age, gender and concurrent illness. 19.2% of the patients (24/125) were prescribed with gabapentin, nortriptyline or gabapentin plus nortriptyline to reduce these peripheral symptoms and 75% of the patients answered the drug were effective. Conclusion: Incidence of PN after cisplatin or oxaliplatin administration is cumulative dose-related. Physician-based assessments under-reported the incidence and severity of CIPN. To overcome this limitation, diagnostic tools specifically designed to assess peripheral neuropathy severity associated with chemotherapy must be developed.
참고문헌 (16)
- Constance Visovsky, "Putting Evidence Into Practice: Evidence-Based Interventions for Chemotherapy-Induced Peripheral Neuropathy", Clinical Journal of Oncology Nursing, 11(6), pp.901~913 (2007)
- 곽미경(Kwak, Mi Kyong), "항암화학요법으로 인한 암환자의 말초신경병증 관련 특성과 삶의 질", Asian Oncology Nursing, 10(2), pp.231~239 (2010), 대한종양간호학회
- Frederick H. Hausheera, "Diagnosis, Management, and Evaluation of Chemotherapy-Induced Peripheral Neuropathy", Semin Oncol, 33, pp.15~49 (2006)
- Katsumasa Kuroi, "A Questionnaire Survey of Physicians' Perspectives Regarding the Assessment of Chemotherapyinduced Peripheral Neuropathy in Patients with Breast Cancer", Jpn J Clin Oncol, 38(11), pp.748~754 (2008)
- Gore M, "Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group", J Clin Oncol, 16(7), pp.2426~2434 (1998)
- McGuire WP, "How many morenails to seal the coffin of dose intensity?", Ann Oncol, 8(4), pp.311~313 (1997)
- Thigpen JT, "Dose-intensity in ovarian carcinoma: hold, enough?", J Clin Oncol, 15(4), pp.1291~1293 (1997)
- Andreas A.Argyriou, "Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies", J Neurol, 252, pp.1459~1464 (2005)
- Gamelin L, "Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer", Clin Cancer Res, 10, pp.4055~4061 (2004)
- de Gramont A, "Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer", J Clin Oncol, 18, pp.2938~2947 (2000)
- 박애령, "진행성 또는 전이성 위암 환자에 있어서 Oxaliplatin 투여로 인한 말초신경통증 분석", 한국임상약학회지, 19(1), pp.18~22 (2009), 한국임상약학회
- Nordlinger B, "Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectalbe liver metastases from colorectal cancer: a randomized controlled trial", Lancet, 371, pp.1007~1016 (2008)
- Jong Gwang Kim, "Cisplatin-induced peripheral neuropathy in patients with advanced gastric cancer", The Korea Journal of Gastroenterology, 36(5), pp.614~621 (2000)
- D. J. Storey, "Capecitabine Combined with Oxaliplatin(CapOx) in Clinical Practice: How Significnat is Peripheral Neuropathy?", Annals of Oncology, 21(8), pp.1657~1661 (2010)
- Gamelin E, "Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventative measures", Semin Oncol, 29(5), pp.21~33 (2002)
- Susanna B. Park, "Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy", Brain, 132, pp.2712~2723 (2009)